Trial · NCT06976892
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
NCT06976892, Phase 1, Recruiting, Institute of Cancer Research, United Kingdom
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer. Trials, record NCT06976892. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06976892
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
- NCT number
- NCT06976892
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Institute of Cancer Research, United Kingdom
- Conditions
- High Grade Serous Ovarian Cancer
- Interventions
- Dose Level 2 (starting dose), Dose Level 1, Dose Level -1, Dose Level 3, Maximum Tolerated Dose
- First posted
- 2025-05-16
- Last updated
- 2025-08-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Propose a recommended dose/schedule for Phase II evaluation of the combination of Idetrexed and Olaparib | End of Cycle 2 (each cycle is 28 days) | Endpoint: Maximum tolerated dose/ schedule (MTD) of the combination of Idetrexed and Olaparib based on dose-limiting toxicities (DLT) with target acceptable DLT rate of 25%, and the Recommended Phase II dose (RP2D) and schedule (Dose Escalation only). |
| Primary | Assess the safety and toxicity profile of Idetrexed and Olaparib | End of Cycle 6 (each cycle is 28 days) | Endpoint: determining causality of each adverse event to Idetrexed and Olaparib and grading severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Dose Escalation and Dose Expansion). |
| Primary | Evaluate the preliminary anti-tumour activity of the combination of Idetrexed and Olaparib in alpha folate receptor overexpressing high grade serous ovarian cancer | Until patient withdraws due to radiological progression, or begins new line of therapy. | Endpoint: Objective response rate by the occurrence of Best Overall Response (BOR) per RECIST 1.1 criteria (Dose Expansion only). |
| Secondary | Evaluate antitumour activity of the combination of Idetrexed and Olaparib | From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Endpoint: Progression Free Survival (PFS). |
| Secondary | Evaluate the preliminary anti-tumour activity of the combination of Idetrexed and Olaparib in ovarian cancer irrespective of alpha folate receptor expression status | From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | Objective response rate. |
| Secondary | CA125 responses | From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | Measurement of CA125 levels. |
| Other | (Tertiary Objective): Retrospective evaluation of response biomarkers | Within four weeks of patient beginning treatment. | Alpha-folate expression. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06976892
GET https://conductscience.org/api/trials/v1/NCT06976892/registered